Bevacizumab as a steroid‐sparing agent during immunotherapy for melanoma brain metastases: A case series

BACKGROUND: Brain metastases are common in advanced melanoma and often necessitate corticosteroids such as dexamethasone to control symptoms and reduce peritumoral edema. Immunotherapy improves survival in metastatic melanoma, but concomitant treatment with corticosteroids may reduce efficacy. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Banks, Patricia D., Lasocki, Arian, Lau, Peter K. H., Sandhu, Shahneen, McArthur, Grant, Shackleton, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427059/
https://www.ncbi.nlm.nih.gov/pubmed/30937392
http://dx.doi.org/10.1002/hsr2.115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427059/
https://www.ncbi.nlm.nih.gov/pubmed/30937392
http://dx.doi.org/10.1002/hsr2.115

Ejemplares similares